Omacor (Omega-3-Acid Ethyl Esters 90)

Omega-3-acid ethyl esters, the active ingredient in Omacor, is a omega-3 fatty acid presented as a 90% oral formulation for oral use. It is prescribed to lower elevated triglyceride concentrations in adults with hypertriglyceridemia and related lipid disorders. Omacor is manufactured under EU pharmaceutical standards and is available only with a prescription.

GNH USA supplies Omacor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omacor is an omega‑3 fatty acid medication used to manage disorders of triglyceride metabolism. - Hypertriglyceridemia: lowers plasma triglyceride levels to reduce cardiovascular risk. - Familial hypertriglyceridemia: helps achieve target triglyceride concentrations in genetically predisposed patients. - Secondary hypertriglyceridemia (e.g., diabetes, metabolic syndrome): contributes to overall lipid control alongside lifestyle measures.

Adverse reactions may occur with Omacor and are categorized by frequency.

Common Side Effects: - Fish‑oil aftertaste: mild, transient taste disturbance. - Gastrointestinal upset: nausea, abdominal discomfort, or dyspepsia. - Diarrhea: loose stools occurring during initial therapy. - Belching: occasional eructation with a fishy odor. - Flatulence: increased intestinal gas. - Mild headache: occasional tension‑type headache.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring medical attention. - Allergic reactions: rash, pruritus, or angioedema. - Bleeding tendency: prolonged bleeding when combined with anticoagulants. - Elevated liver enzymes: transaminase increases indicating hepatic stress. - Atrial fibrillation: rare cardiac rhythm disturbances.

Before initiating Omacor, clinicians should consider several safety measures. - Monitor triglyceride levels: assess response and adjust therapy as needed. - Assess liver function: obtain baseline and periodic hepatic enzyme tests. - Evaluate bleeding risk: review concomitant anticoagulant or antiplatelet use. - Counsel on dietary fish intake: avoid excessive omega‑3 consumption from other sources. - Review pregnancy and lactation status: weigh potential benefits against unknown risks. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Omacor may interact with other medicines, requiring attention to the interaction strength.

Major Interactions (Avoid): - Warfarin or other oral anticoagulants: increased bleeding risk. - Antiplatelet agents (e.g., clopidogrel): additive antithrombotic effect. - High‑dose vitamin E supplements: potential for enhanced anticoagulation.

Moderate Interactions (Monitor Closely): - Statins: monitor for myopathy when combined with high‑dose omega‑3. - Fibrates: assess for additive triglyceride‑lowering effect and liver enzymes. - Blood pressure medications: observe for modest blood pressure reduction. - Other omega‑3 preparations: avoid duplicate therapy to prevent excess dosing. - Immunosuppressants: monitor for possible alterations in drug metabolism.